文献速递前列腺癌

镭-223治疗转移性去势抵抗性前列腺癌患者骨代谢标志物与生存的前瞻性评估:PRORADIUM研究

Prospective Assessment of Bone Metabolism Biomarkers and Survival in Metastatic Castration-resistant Prostate Cancer Patients Treated with Radium-223: The PRORADIUM Study.
PubMed 文献 · Eur Urol Oncol · 2023-10-12

PRORADIUM前瞻性队列纳入169例接受镭-223治疗的转移性去势抵抗性前列腺癌患者,评估基线骨形成与骨吸收标志物与生存的关联。多变量分析中仅基线骨碱性磷酸酶(BAP)高与生存独立相关(HR 1.89),将其加入临床模型使2年AUC从0.667升至0.755。

要点

  • 基线BAP高与生存独立相关,多变量HR 1.89(95%CI 1.28-2.79,p=0.001)。
  • 至少3种骨代谢标志物高者单变量生存更差(9.9 vs 15.2个月,HR 1.8),多变量分析未达独立。
  • BAP加入多变量临床模型使2年AUC从0.667升至0.755(p=0.003)。

核心结论

  • 骨形成标志物尤其是BAP在镭-223治疗的mCRPC患者中具有预后价值。
  • BAP的预测价值仍需评估,理想情况下应在前瞻性、有足够把握度的随机临床试验中进行。

研究设计与样本

  • 前瞻性队列研究(PRORADIUM研究:NCT02925702),纳入169例接受镭-223治疗的mCRPC患者。
  • 主要目的为评估基线时至少三种骨形成标志物(骨碱性磷酸酶[BAP]和I型胶原C端前肽)与骨吸收标志物(N端端肽和吡啶啉)高值(≥中位数)与生存的关联。
  • 采用多变量Cox回归模型评估。

主要发现

  • 70.4%的患者接受镭-223为二线/三线治疗;144例(85.2%)为ECOG 0-1,126例(74.6%)有疼痛,80例(47.5%)骨转移灶超过10个。
  • 67例(39.6%)患者至少三种骨代谢标志物升高。
  • 中位总生存为12.1个月(95%CI 10-14.7)。
  • 至少三种骨代谢标志物高值者单变量分析生存显著更差(9.9 vs 15.2个月;HR 1.8[95%CI 1.3-2.5];p<0.001),但多变量分析未达独立(HR 1.33;95%CI 0.89-2;p=0.181)。
  • 基线BAP高是唯一在多变量模型中与生存相关的标志物(HR 1.89;95%CI 1.28-2.79;p=0.001);将BAP加入多变量临床模型使2年ROC曲线下面积从0.667升至0.755(p=0.003)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Radium-223 is an active therapy option for bone metastatic castration-resistant prostate cancer (mCRPC). The lack of adequate biomarkers for patient selection and response assessment are major drawbacks for its use. OBJECTIVE: To assess the prognostic value of bone metabolism biomarkers (BMBs) in ra-223-treated mCRPC patients. DESIGN, SETTING, AND PARTICIPANTS: A prospective cohort study of mCRPC patients treated with Ra-223 (PRORADIUM study: NCT02925702) was conducted. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The main objective of the study was to evaluate the association between high (≥median) baseline values in at least three bone formation (bone alkaline phosphatase [BAP] and C-terminal type-I collagen propeptide) and bone resorption (N-terminal telopeptide and pyridinoline) biomarkers, and survival. The independent prognostic value of each BMB was also assessed. The association with time to radiographic, clinical, and prostate-specific antigen (PSA) progression; time to skeletal-related events; and PSA response were secondary objectives. Multivariable (MV) Cox-regression models were evaluated. RESULTS AND LIMITATIONS: A total of 169 patients were included. Of the patients, 70.4% received Ra-223 in second/third line; 144 (85.2%) were Eastern Cooperative Oncology Group 0-1, 126 (74.6%) were in pain, and 80 (47.5%) had more than ten bone metastases. Sixty-seven (39.6%) patients had elevation in at least three BMBs. The median overall survival was 12.1 mo (95% confidence interval [CI]: 10-14.7). No association was observed with other treatment-related secondary outcome parameters. Patients with high values in three or more BMBs had significantly worse survival (9.9 vs 15.2 mo; hazard ratio [HR]: 1.8 [95% CI: 1.3-2.5]; p < 0.001) in the univariate analysis, but not independent in the MV analysis (HR: 1.33; 95% CI: 0.89-2; p = 0.181). High baseline BAP was the only biomarker associated with survival in the MV model (HR: 1.89; 95% CI: 1.28-2.79; p = 0.001). Addition of BAP to the MV clinical model increased the area under the receiver operating characteristic curve 2-yr value from 0.667 to 0.755 (p = 0.003). CONCLUSIONS: Biomarkers of bone formation, especially BAP, have prognostic value in mCRPC patients treated with radium-223. Its predictive value remains to be assessed, ideally in prospective, adequately powered, randomised clinical trials. PATIENT SUMMARY: In this study, we evaluate the role of bone metabolism biomarkers to help improve the use of radium-223 as therapy for advanced prostate cancer. We found that bone alkaline phosphatase may be a suitable tool.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Romero-Laorden N, Lorente D, de Velasco G, et al. Prospective Assessment of Bone Metabolism Biomarkers and Survival in Metastatic Castration-resistant Prostate Cancer Patients Treated with Radium-223: The PRORADIUM Study. Eur Urol Oncol. 2023. PMID: 37838555. doi:10.1016/j.euo.2023.09.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。